Journal Watch · Pharmacological Reviews · 2026
Carbon dots for drug delivery: Insights into their potential in nanopharmacology.
By enabling targeted, multifunctional, and trackable therapeutic strategies across cancer, viral infections, osteoarticular, and neurological diseases, carbon dots offer a unique platform that bridges diagnostics and therapy, with the potential to significantly advance precision medicine while addressing current limitations of conventional drug carriers.
TL;DR
By enabling targeted, multifunctional, and trackable therapeutic strategies across cancer, viral infections, osteoarticular, and neurological diseases, carbon dots offer a unique platform that bridges diagnostics and therapy, with the potential to significantly advance precision medicine while addressing current limitations of conventional drug carriers.
Key findings
- These promising developments position CDs as cutting-edge tools in nanopharmacology, offering exciting opportunities for future therapeutic innovations.
- SIGNIFICANCE STATEMENT: Carbon dots represent a transformative class of nanomaterials whose tunable chemistry, intrinsic photoluminescence, and high biocompatibility make them highly promising for next-generation drug delivery.
- By enabling targeted, multifunctional, and trackable therapeutic strategies across cancer, viral infections, osteoarticular, and neurological diseases, carbon dots offer a unique platform that bridges diagnostics and therapy, with the potential to significantly advance precision medicine while addressing current limitations of conventional drug carriers.
What they did
This versatility enables the conjugation of various functional groups, therapeutic molecules, biomolecules, and targeting ligands, paving the way for an integrated approach to diagnosis and therapy. This review highlights the latest advancements in the application of CDs for drug delivery, focusing on their use in anticancer and antiviral therapies, as well as in the treatment of osteoarticular diseases and neurological disorders. Particular attention is given to the critical aspects of biocompatibility and toxicity, which remain key challenges for their translation into clinical practice.
Full abstract (original)
Background: Carbon dots (CDs), a remarkable class of novel nanomaterials, have attracted significant attention in the biomedical field owing to their extraordinary chemical, physical, and biological properties. Among their diverse applications, CDs stand out as highly promising nanocarriers for drug delivery owing to their ability to cross cell membranes efficiently and deliver therapeutic agents directly to damaged cells or tissues. What makes CDs truly unique is their intrinsic photoluminescence and the abundance of reactive groups on their surface, allowing for extensive multifunctionalization.
What they did: This versatility enables the conjugation of various functional groups, therapeutic molecules, biomolecules, and targeting ligands, paving the way for an integrated approach to diagnosis and therapy. This review highlights the latest advancements in the application of CDs for drug delivery, focusing on their use in anticancer and antiviral therapies, as well as in the treatment of osteoarticular diseases and neurological disorders. Particular attention is given to the critical aspects of biocompatibility and toxicity, which remain key challenges for their translation into clinical practice.
Results & conclusions: These promising developments position CDs as cutting-edge tools in nanopharmacology, offering exciting opportunities for future therapeutic innovations. SIGNIFICANCE STATEMENT: Carbon dots represent a transformative class of nanomaterials whose tunable chemistry, intrinsic photoluminescence, and high biocompatibility make them highly promising for next-generation drug delivery. By enabling targeted, multifunctional, and trackable therapeutic strategies across cancer, viral infections, osteoarticular, and neurological diseases, carbon dots offer a unique platform that bridges diagnostics and therapy, with the potential to significantly advance precision medicine while addressing current limitations of conventional drug carriers.
Abstract © the authors / Pharmacological Reviews (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.pharmr.2025.100107 · PubMed 41759375.
Why it matters for pharma & biotech
- Relevant to Pharmacology & Drug Discovery teams tracking Pharmacological Reviews for new targets, mechanisms and biomarkers.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- As a review, this paper synthesises prior studies rather than reporting new experimental data; weight it accordingly.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Pharmacological Reviews study find?
By enabling targeted, multifunctional, and trackable therapeutic strategies across cancer, viral infections, osteoarticular, and neurological diseases, carbon dots offer a unique platform that bridges diagnostics and therapy, with the potential to significantly advance precision medicine while addressing current limitations of conventional drug carriers.
What type of study is this?
It is a review / perspective, published in Pharmacological Reviews in 2026. This versatility enables the conjugation of various functional groups, therapeutic molecules, biomolecules, and targeting ligands, paving the way for an integrated approach to diagnosis and therapy.
Where can I read the original paper?
The original is at the publisher via DOI 10.1016/j.pharmr.2025.100107. PubMed ID: 41759375. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/carbon-dots-for-drug-delivery-insights-into-their-potential-in-nanopharm-100107/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides